Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma

Molecular and Cellular Proteomics

Volumn 4, Issue 4, 2005, Pages 346-355

  Sheehan, Katherine M ^a,b   Calvert, Valerie S ^a   Kay, Elaine W ^b   Lu, Yiling ^c   Fishman, David ^d   Espina, Virginia ^a   Aquino, Joy ^a   Speer, Runa ^a   Araujo, Robyn ^a   Mills, Gordon B ^c   Liotta, Lance A ^a   Petricoin III, Emanuel F ^a   Wulfkuhle, Julia D ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b BEAUMONT HOSPITAL   (Ireland)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BEVACIZUMAB; CETUXIMAB; CISPLATIN; COMPLEMENTARY DNA; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; IMATINIB; MARCKS PROTEIN; PEPTIDE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR;

ARTICLE; CANCER INHIBITION; CANCER PATIENT; CANCER STAGING; CLINICAL PROTOCOL; DNA PROTEIN COMPLEX; DRUG TARGETING; ENZYME INHIBITION; FEMALE; GENE EXPRESSION PROFILING; GENE MAPPING; GENETIC ANALYSIS; HUMAN; MICROENVIRONMENT; MOLECULAR BIOLOGY; OVARY METASTASIS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN ANALYSIS; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; STANDARDIZATION; TREATMENT OUTCOME;

CARCINOMA; FEMALE; HUMANS; MOLECULAR BIOLOGY; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PEPTIDES; PHOSPHORYLATION; PROTEIN ARRAY ANALYSIS; PROTEOMICS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 17844377553     PISSN: 15359476     EISSN: None     Source Type: Journal    
DOI: 10.1074/mcp.T500003-MCP200     Document Type: Article

References (79)

1. Liotta, L. A., Espina, V., Mehta, A. I., Calvert, V., Rosenblatt, K., Geho, D., Munson, P. J., Young, L., Wulfkuhle, J., and Petricoin, E. F., III. (2003) Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 3, 317-325
2. Pavlickova, P., Schneider, E. M., and Hug, H. (2004) Advances in recombinant antibody microarrays. Clin. Chim. Acta 343, 17-35
3. Lal, S. P., Christopherson, R. I., and dos Remedios, C. G. (2002) Antibody arrays: an embryonic but rapidly growing technology. Drug Discov. Today 7, S143-S149
4. Templin, M. F., Stoll, D., Schrenk, M., Traub, P. C., Vohringer, C. F., and Joos, T. O. (2002) Protein microarray technology. Trends Biotechnol. 20, 160-166
5. Petach, H., and Gold, L. (2002) Dimensionality is the issue: use of photoaptamers in protein microarrays. Curr. Opin. Biotechnol. 13, 309-314
6. Kukar, T., Eckenrode, S., Gu, Y., Lian, W., Megginson, M., She, J.-X., and Wu, D. (2002) Protein microarrays to detect protein-protein interactions using red and green fluorescent proteins. Anal. Biochem. 306, 50-54
7. Hunter, T. (2000) Signaling - 2000 and beyond. Cell 100, 113-127
8. Blume-Jensen, P., and Hunter, T. (2001) Oncogenic kinase signalling. Nature 411, 355-365
9. Celis, J. E., and Gromov, P. (2003) Proteomics in translational cancer research: toward an integrated approach. Cancer Cell 3, 9-15
10. Jeong, H., Tombor, B., Albert, R., Oltvai, Z. N., and Barabasi, A. L. (2000) The large-scale organization of metabolic networks. Nature 407, 651-654
11. Charboneau, L. (2002) Utility of reverse phase protein microarrays: applications to signaling pathways and human body arrays. Brief. Funct. Genomics Proteomics 1, 305-315
12. Cutler, P. (2003) Protein arrays: the current state-of-the-art. Proteomics 3, 3-18
13. Ge, H. (2000) UPA, a universal protein array system for quantitative detection of protein-protein, protein-DNA, protein-RNA and protein-ligand interactions. Nucleic Acids Res. 28, e3 i-iii
14. MacBeath, G. (2002) Protein microarrays and proteomics. Nat. Genet. 32, (suppl.) 526-532
15. MacBeath, G., and Schreiber, S. L. (2000) Printing proteins as microarrays for high-throughput function determination. Science 289, 1760-1763
16. Miller, J. C., Zhou, H., Kwekel, J., Cavalio, R., Burke, J., Butler, E. B., Teh, B. S., and Haab, B. B. (2003) Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 3, 56-63
17. Paweletz, C. P., Charboneau, L., Bichsel, V. E., Simone, N. L., Chen, T., Gillespie, J. W., Emmert-Buck, M. R., Roth, M. J., Petricoin, E. F., III, and Liotta, L. A. (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981-1989
18. Wilson, D. S., and Nock, S. (2003) Recent developments in protein microarray technology. Angew. Chem. Int. Ed. Engl. 42, 494-600
19. Zhu, H., and Snyder, M. (2001) Protein arrays and microarrays. Curr. Opin. Chem. Biol. 5, 40-45
20. Zhu, H., and Snyder, M. (2003) Protein chip technology. Curr. Opin. Chem. Biol. 7, 55-63
21. Liotta, L. A., Kohn, E. C., and Petricoin, E. F. (2001) Clinical proteomics: personalized molecular medicine. J. Am. Med. Assoc. 286, 2211-2214
22. Petricoin, E. F., Zoon, K. C., Kohn E. C., Barrett, J. C., and Liotta, L. A. (2002) Clinical proteomics: translating benchside promise into bedside reality. Nat. Rev. Drug Discov. 1, 683-695
23. Espina, V., Dettloff, K. A., Cowherd, S., Petricoin, E. F., III, and Liotta, L. A. (2004) Use of proteomic analysis to monitor responses to biological therapies. Expert Opin. Biol. Ther. 4, 83-93
24. Zha, H., Raffeld, M., Charboneau, L., Pittaluga, S., Kwak, L. W., Petricoin, E., III, Liotta, L. A., and Jaffe, E. S. (2004) Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab. Investig. 84, 235-244
25. Carr, K. M., Rosenblatt, K., Petricoin, E. F., and Liotta, L. A. (2004) Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. Hum. Genomics 1, 134-140
26. Grubb, R. L., Calvert, V. S., Wulfkuhle, J. D., Paweletz, C. P., Linehan, W. M., Phillips, J. L., Chuaqui, R., Valasco, A., Gillespie, J., Emmert-Buck, M., Liotta, L. A., and Petricoin, E. F. (2003) Signal pathway profiling of prostate cancer using reverse phase protein microarrays. Proteomics 3, 2142-2146
27. Wulfkuhle, J. D., Aquino, J. A., Calvert, V. S., Fishman, D. A., Coukos, G., Liotta, L. A., and Petricoin, E. F., III (2003) Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 3, 2085-2090
28. Nishizuka, S., Chen, S.-T., Gwadry, F. G., Alexander, J., Major, S. M., Scharf, U., Reinhold, W. C., Waltham, M., Charboneau, L., Young, L., Bussey, K. J., Kim, S., Lababidi, S., Lee, J. K., Pittaluga, S., Scudiero, D. A., Sausville, E. A., Munson, P. J., Petricoin, E. F., III, Liotta, L. A., Hewitt, S. M., Raffeld, M., and Weinstein, J. N. (2003) Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res. 63, 5243-5250
29. Nishizuka, S., Charboneau, L., Young, L., Major, S., Reinhold, W. C., Waltham, M., Kouros-Mehr, H., Bussey, K. J., Lee, J. K., Espina, V., Munson, P. J., Petricoin, E., III, Liotta, L. A., and Weinstein, J. N. (2003) Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl. Acad. Sci. U. S. A. 100, 14229-14234
30. Calvert, V. S., Tang, Y., Boveia, V., Wulfkuhle, J., Schutz-Geschwender, A., Olive, D. M., Liotta, L. A., and Petricoin, E. F. (2004) Development of multiplexed protein profiling and detection using near infrared detection of reverse phase protein microarrays. Clin. Prot. 1, 81-89
31. Geho, D. H., Lahar, N., Ferrari, M., Petricoin, E. F., and Liotta, L. A. (2004) Opportunities for nanotechnology-based innovation in tissue proteomics. Biomed. Microdevices 6, 231-239
32. Espina, V., Woodhouse, E. C., Wulfkuhle, J., Asmussen, H. D., Petricoin, E. F., III, and Liotta, L. A. (2004) Protein microarray detection strategies: focus on direct detection methods. J. Immunol. Methods 290, 121-133
33. Torhorst, J., Bucher, C., Kononen, J., Haas, P., Zuber, M., Kochli, O. R., Mross, F., Dieterich, H., Moch, H., Mihatsch, M., Kallioniemi, O.-P., and Sauter, G. (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am. J. Pathol. 159, 2249-2256
34. Sreekumar, A., Nyati, M. K., Varambally, S., Barrette, T. R., Ghosh, D., Lawrence, T. S., and Chinnaiyan, A. M. (2001) Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res. 61, 7585-7593
35. Knezevic, V., Leethanakul, C., Bichsel, V. E., Worth, J. M., Prabhu, V. V., Gutkind, J. S., Liotta, L. A., Munson, P. J., Petricoin, E. F., III, and Krizman, D. B. (2001) Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics 1, 1271-1278
36. Espina, V., Mehta, A. I., Winters, M. E., Calvert, V., Wulfkuhle, J., Petricoin, E. F., III, and Liotta, L. A. (2003) Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 3, 2091-2100
37. Celis, J. E., Moreira, J. M., Gromova, I., Cabezon, T., Ralfkiaer, U., Guldberg, P., Straten, P. T., Mouridsen, H., Friis, E., Holm, D., Rank, F., and Gromov, P. (2005) Towards discovery-driven translational research in breast cancer. FEBS J. 272, 2-15
38. Tolcher, A. W., Reyno, L., Venner, P. M., Ernst, S. D., Moore, M., Geary, R. S., Chi, K., Hall, S., Walsh, W., Dorr, A., and Eisenhauer, E. (2002) A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 inpatients with hormone-refractory prostate cancer. Clin. Cancer Res. 8, 2530-2535
39. Agarwal, R., and Kaye, S. B. (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 3, 502-516
40. See, H. T., and Kavanagh, J. J. (2004) Novel agents in epithelial ovarian cancer. Cancer Investig. 22, Suppl. 2, 29-44
41. Mendelsohn, J., and Baselga, J. (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21, 2787-2799
42. Sewell, J. M., Macleod, K. G., Ritchie, A., Smyth, J. F., and Langdon, S. P. (2002) Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa"). Br. J. Cancer 86, 456-462
43. Ferrara, N. (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 10-14
44. Sattler, M., and Salgia, R. (2004) Targeting c-Kit mutations: basic science to novel therapies. Leukoc. Res. 28, Suppl. 1, S11-S20
45. Liotta, L. A., and Kohn, E. C. (2001) The microenvironment of the tumour-host interface. Nature 411, 375-379
46. Emmert-Buck, M. R., Bonner, R. F., Smith, P. D., Chuaqui, R. F., Zhuang, Z., Goldstein, S. R., Weiss, R. A., and Liotta, L. A. (1996) Laser capture microdissection. Science 274, 998-1001
47. Partridge, E. E., and Barnes, M. N. (1999) Epithelial ovarian cancer: prevention, diagnosis and treatment. Can. Cancer J. Clin. 49, 297-320
48. Joliffe, T. (1986) Principle Components Analysis, pp. 1-15, Springer, Berlin
49. Kurella, M., Hsiao, L. L., Yshida, T., Randall, J. D., Chow, G., Sarang, S. S., Jensen, R. V., and Gullens, S. R. (2001) DNA microarray analysis of complex biologic processes. J. Am. Soc. Nephrol. 12, 1072-1078
50. Iwafuchi, H. (2004) Principle component analysis of salivary gland tumors. Mod Pathol. 17, 803-810
51. Ciampi, A., Lawless, J. F., McKinney, S. M., and Singhal, K. (1988) Regression and recursive partition strategies in the analysis of medical survival data. J. Clin. Epidemiol. 41, 737-748
52. Lu, K. H., Patterson, A. P., Wang, L., Marquez, R. T., Atkinson, E. N., Baggerly, K. A., Ramoth, L. R., Rosen, D. G., Liu, J., Hellstrom, I., Smith, D., Hartmann, L., Fishman, D., Berchuck, A., Schmandt, R., Whitaker, R., Gershenson, D. M., Mills, G. B., and Bast, R. C., Jr. (2004) Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 10, 3291-3300
53. Akin, C., and Metcalfe, D. D. (2004) The biology of Kit in disease and the application of pharmacogenetics. J. Allergy Clin. Immunol. 114, 13-19
54. Tse, G. M., Putti, T. C., Lui, P. C., Lo, A. W., Scolyer, R. A., Law, B. K., Karim, R., and Lee, C. S. (2004) Increased c-kit (CD117) expression in malignant mammary phyllodes tumors. Mod. Pathol. 17, 827-831
55. Schmandt, R. E., Broaddus, R., and Lu, K. H. (2003) Platelet-derived growth factor receptor in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer 98, 758-764
56. Raspollini, M. R., Amunni, G., Villanucci, A., Baroni, G., Taddei, A., and Taddei, G. L. (2004) c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study. Ann. Oncol. 16, 594-597
57. Hanash, S. (2003) Disease proteomics. Nature 422, 226-232
58. Tyers, M., and Mann, M. (2003) From genomics to proteomics. Nature 422, 193-197
59. Agaton, C., Galli, J., Hoiden Guthenberg, I., Janzon, L., Hansson, M., Asplund, A., Brundell, E., Lindberg, S., Ruthberg, I., Wester, K., Wurtz, D., Hoog, C., Lundeberg, J., Stahl, S., Ponten, F., and Uhlen, M. (2003) Affinity proteomics for systematic protein profiling of chromosome 21 gene products in human tissues. Mol. Cell. Proteomics. 2, 405-414
60. Ntzani, E. E., and Ioannidis, J. P. (2003) Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 362, 1439-1444
61. Cronin, M., Ghosh, K., Sistare, F., Quackenbush, J., Vilker, V., and O'Connell, C. (2004) Universal RNA reference materials for gene expression. Clin. Chem. 50, 1464-1471
62. Petricoin, E., Wulfkuhle, J., Espina, V., and Liotta, L. A. (2004) Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. J. Proteome Res. 3, 209-217
63. Araujo, R. P., Doran, C., Liotta, L. A., and Petricoin, E. F. (2005) Network-targeted combination therapy: a new concept in cancer treatment. Drug Discov. Today 1, 425-433
64. Araujo, R. P., Petricoin, E. F., and Liotta, L. A. (2005) A mathematical model of combination therapy using the EGFR signaling network. Biosystems, in press
65. Bray, D. (2003) Molecular networks: the top-down view. Science 301, 1864-1865
66. Ponder, B. A. (2001) Cancer genetics. Nature 411, 337-341
67. Evan, G. I., and Vousden, K. H. (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342-348
68. Kaptain, S., Tan, L. K., and Chen, B. (2001) Her-2/neu and breast cancer. Diagn. Mol. Pathol. 10, 139-152
69. Leyland-Jones, B. (2002) Trastuzumab: hopes and realities. Lancet Oncol. 3, 137-144
70. Sebolt-Leyopold, J. S. (2000) Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 19, 6594-6599
71. Santen, R. J., Song, R. X., McPherson, R., Kumar, R., Adam, L., Jeng, M. H., and Yue, W. (2002) The role of mitogen-activated protein (MAP) kinase in breast cancer. J. Steroid Biochem. Mol. Biol. 80, 239-256
72. Sebolt-Leyopold, J. S., and Herrera, R. (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4, 937-947
73. Keen, N., and Taylor, S. (2004) Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer 4, 927-936
74. Traxler, R., Bold, G., Buchdunger, E., Caravatti, G., Furet, P., Manley, P., O'Reilly, T., Wood, J., and Zimmermann, J. (2001) Tyrosine-kinase inhibitors: from rational design to clinical trials. Med. Res. Rev. 21, 499-512
75. Zwick, E., Bange, J., and Ullrich, A. (2001) Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol. Med. 8, 17-23
76. Normanno, N., Campiglio, M., De, L. A., Somenzi, G., Maiello, M., Ciardiello, F., Giani, L., Salomon, D. S., and Menard, S. (2002) Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol. 13, 65-72
77. Moasser, M. M., Basso, A., Averbuch, S. D., and Rosen, N. (2001) The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 61, 7184-7188
78. Cuello, M., Ettenberg, S. A., Clark, A. S., Keane, M. M., Posner, R. H., Nau, M. M., Dennis, P. A., and Lipkowitz, S. (2001) Down-regulation of the erbB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 61, 4892-4900
79. Herbst, R. S., Fukuoka, M., and Baselga, J. (2004) Gefitinib - a novel targeted approach to treating cancer. Nat Rev. Cancer 4, 956-965